Mortality (12 months · newly diagnosed patients with myelodysplastic syndromes
GM‐CSF showed no clear difference in mortality (12 months compared with placebo (low certainty).
1 finding from 1 review
Progression‐free survival · newly diagnosed patients with myelodysplastic syndromes
1 finding from 1 review
Number of participants with any bleeding · People with a haematological disorder
1 finding from 1 review
Thromboembolism · People with a haematological disorder
1 finding from 1 review
Mortality (all‐cause) ‐ not reported · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Adverse events associated with transfusion · People with a haematological disorder
1 finding from 1 review
Adverse events of antifibrinolytic agents · People with a haematological disorder
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
1 finding from 1 review
Number of participants with at least 1 bleeding episode · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
It is very uncertain whether thrombopoietin mimetics changes number of participants with at least 1 bleeding episode compared with placebo or standard care (very low certainty).
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
It is very uncertain whether thrombopoietin mimetics changes number of participants with severe or life‐threatening bleeding compared with placebo or standard care (very low certainty).
1 finding from 1 review
Number of days on which bleeding occurred ‐ not measured · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to first bleeding episode (days) · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
no estimate extracted
4 participants
GRADE not reported
Number of platelet transfusions per participant up to 30 days from study entry · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
Thromboembolic events · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
Quality of life ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 bleeding episode · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in number of participants with at least one bleeding episode compared with placebo (low certainty).
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in number of participants with at least one severe or life‐threatening… compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review